Abbott EVP awarded stock options and shares

ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares.

Rhea-AI Filing Summary

ABBOTT LABORATORIES executive Christopher J. Scoggins reported equity awards consisting of stock options and performance-based shares. He received an employee stock option for 76,273 common shares at an exercise price of $0.0000 per share, granted under the Abbott Laboratories 2017 Incentive Stock Program.

The option becomes exercisable in three annual increments of 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029. He was also granted 18,502 common shares as a performance-based restricted stock award with a three-year term, with no more than one‑third vesting in any year upon Abbott reaching a minimum return on equity target, and the award allows shares to be withheld for taxes.

Insider Trade Summary

Grant/Award: 94,775 shares

Grant/Award 2 txns

Insider Scoggins Christopher J

Role EXECUTIVE VICE PRESIDENT

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	76,273	$0.00	$0.00
Grant/Award	Common shares without par value	18,502	$0.00	$0.00

Holdings After Transaction: Option (right to buy) — 76,273 contracts (Direct); Common shares without par value — 82,123 shares (Direct)

Footnotes (2)

1. F1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
2. F2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,424 on February 24, 2027, 25,424 on February 24, 2028, and 25,425 on February 24, 2029.

FAQ

What did Abbott Laboratories (ABT) executive Christopher J. Scoggins receive in this Form 4 filing?

Christopher J. Scoggins reported receiving an employee stock option and a performance-based restricted stock award. The option covers 76,273 common shares, while the restricted stock award covers 18,502 common shares, all granted under the Abbott Laboratories 2017 Incentive Stock Program.

How do the new Abbott (ABT) stock options granted to Christopher J. Scoggins vest?

The employee stock option for 76,273 Abbott common shares vests in three annual tranches. It becomes exercisable for 25,424 shares on February 24, 2027, 25,424 shares on February 24, 2028, and 25,425 shares on February 24, 2029, according to the grant terms.

What are the terms of the performance-based restricted stock award reported for ABT’s Christopher J. Scoggins?

The performance-based restricted stock award covers 18,502 Abbott common shares over a three-year term. No more than one-third of the award may vest in any single year, and vesting depends on Abbott reaching a minimum return on equity target specified in the incentive program.

Does the Abbott (ABT) performance-based restricted stock award allow tax withholding in shares?

Yes. The performance-based restricted stock award granted to Christopher J. Scoggins includes the right to have shares withheld for tax purposes. This means a portion of vested shares can be retained by Abbott to satisfy applicable tax withholding obligations.

Under which plan were Christopher J. Scoggins’s Abbott (ABT) equity awards granted?

Both the employee stock option and the performance-based restricted stock award for Christopher J. Scoggins were granted under the Abbott Laboratories 2017 Incentive Stock Program, which governs vesting schedules, performance conditions, and related terms for these equity incentives.

Are the equity awards to Abbott (ABT) executive Christopher J. Scoggins classified as acquisitions or open-market purchases?

The awards are classified as grant or award acquisitions, not open-market purchases. The Form 4 identifies both the stock option and the restricted stock award with transaction code “A,” meaning they are equity grants provided under Abbott’s 2017 Incentive Stock Program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 07:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Scoggins Christopher J

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EXECUTIVE VICE PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		18,502(1)	A	$0	82,123	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(2)	$114.6	02/24/2026		A		76,273		02/24/2027	02/23/2036	Common Shares	76,273	$0	76,273	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 25,424 on February 24, 2027, 25,424 on February 24, 2028, and 25,425 on February 24, 2029.

	/s/ Christopher J. Scoggins by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.